Soleno Therapeutics Plunges 10.81% Amid Investor Sentiment Shift

On August 15, 2025, Soleno Therapeutics experienced a significant drop of 10.81% in pre-market trading, reflecting a notable decline in investor sentiment.

Soleno Therapeutics has received a consensus rating of "Buy" from analysts, with an average price target of $113.30, indicating a potential upside of 46.46%. This positive outlook is supported by the short-term moving average, which suggests a buy signal, although the long-term average indicates a general sell signal.

TD Cowen has maintained a "Buy" rating for Soleno Therapeutics, with a target price of $120, reflecting confidence in the company's future performance. This rating aligns with the overall positive sentiment from analysts, who see potential for significant growth in the stock.